Journal of Clinical Endocrinology & Metabolism, Vol 77, 439-442, Copyright © 1993 by Endocrine Society

ARTICLES

Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition

E le Nestour, J Marraoui, N Lahlou, M Roger, D de Ziegler and P Bouchard
Service d'Endocrinologie et des Maladies de la Reproduction, Hopital de Bicetre, Le Kremlin Bicetre, France.

Follicular recruitment takes place under FSH stimulation at the end of the luteal phase and the beginning of the subsequent follicular phase, the so-called luteal-follicular transition (LFT). Inhibin, a known suppressor of FSH, has been implicated in the onset of the rise in FSH levels, as the fall in its immunoreactive plasma levels after the demise of the corpus luteum has been shown to correlate negatively with the increase in FSH. To analyze the role of estradiol (E2), another inhibitor of FSH secretion in the LFT, we designed an experimental paradigm to dissociate the physiological falls in inhibin and E2. This was achieved by extending the duration of luteal plasma E2 levels with transdermal E2 treatment. Untreated ovulatory cycles in seven healthy female volunteers, aged 28-38 yr, were compared with E2-treated cycles in the same subjects, with treatment starting on the 10th day after the LH surge and continuing through the 4th day of the following menses [either 0.2 mg (n = 6; G1) or 0.1 mg (n = 6; G2) E2 daily]. Blood samples were obtained daily from the LH surge until the 11th day of the next cycle. Immunoreactive plasma inhibin levels reached a nadir on day 2 of menses regardless of whether women received E2. Plasma E2 (mean +/- SEM) levels remained within the normal luteal range (220 +/- 51 to 635 +/- 279 pmol/L) until the end of the treatment period in G2 (range, 253 +/- 40 to 382 +/- 62 pmol/L), but not in G1 (range, 598 +/- 195 to 1835 +/- 1259 pmol/L). However, the onset of the FSH rise was clearly delayed, from a mean of 2 days before menstruation in the controls to day 4 of the cycle in G1 and G2. Peak plasma FSH levels were attained within 6 days in the controls and within 2 or 3 days in both treatment periods. Our data suggest that it is the decrease in plasma E2 rather than inhibin that is the triggering signal for the LFT rise in plasma FSH. The exact roles of inhibin and other gonadal proteins (e.g. activins) in follicular recruitment remain to be determined.

This article has been cited by other articles:

				I. Cedrin-Durnerin, B. Bstandig, I. Parneix, V. Bied-Damon, C. Avril, C. Decanter, and J.N. Hugues Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol Hum. Reprod., January 1, 2007; 22(1): 109 - 116. [Abstract] [Full Text] [PDF]

				I. E. Messinis Ovarian feedback, mechanism of action and possible clinical implications Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571. [Abstract] [Full Text] [PDF]

				N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]

				R. F. Casper and M. F. M. Mitwally Aromatase Inhibitors for Ovulation Induction J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 760 - 771. [Abstract] [Full Text] [PDF]

				H. M. Fraser, H. Wilson, K. D. Morris, I. Swanston, and S. J. Wiegand Vascular Endothelial Growth Factor Trap Suppresses Ovarian Function at All Stages of the Luteal Phase in the Macaque J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5811 - 5818. [Abstract] [Full Text] [PDF]

				C. K. Welt, J. E. Hall, J. M. Adams, and A. E. Taylor Relationship of Estradiol and Inhibin to the Follicle-Stimulating Hormone Variability in Hypergonadotropic Hypogonadism or Premature Ovarian Failure J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 826 - 830. [Abstract] [Full Text] [PDF]

				F. Miro and L.J. Aspinall The onset of the initial rise in follicle-stimulating hormone during the human menstrual cycle Hum. Reprod., January 1, 2005; 20(1): 96 - 100. [Abstract] [Full Text] [PDF]

				D. de Ziegler Associate editor's commentary: The dawning of the non-cancer uses of aromatase inhibitors in gynaecology Hum. Reprod., August 1, 2003; 18(8): 1598 - 1602. [Full Text] [PDF]

				C. K. Welt, Y. L. Pagan, P. C. Smith, K. B. Rado, and J. E. Hall Control of Follicle-Stimulating Hormone by Estradiol and the Inhibins: Critical Role of Estradiol at the Hypothalamus during the Luteal-Follicular Transition J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1766 - 1771. [Abstract] [Full Text] [PDF]

				P.v. Zonneveld, G.J. Scheffer, F.J.M. Broekmans, M.A. Blankenstein, F.H.d. Jong, C.W.N. Looman, J.D.F. Habbema, and E.R.t. Velde Do cycle disturbances explain the age-related decline of female fertility? Cycle characteristics of women aged over 40 years compared with a reference population of young women Hum. Reprod., March 1, 2003; 18(3): 495 - 501. [Abstract] [Full Text] [PDF]

				N. A. Klein, A. J. Harper, B. S. Houmard, P. M. Sluss, and M. R. Soules Is the Short Follicular Phase in Older Women Secondary to Advanced or Accelerated Dominant Follicle Development? J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5746 - 5750. [Abstract] [Full Text] [PDF]

				I. E. Messinis, S. Milingos, E. Alexandris, I. Mademtzis, G. Kollios, and K. Seferiadis Evidence of differential control of FSH and LH responses to GnRH by ovarian steroids in the luteal phase of the cycle Hum. Reprod., February 1, 2002; 17(2): 299 - 303. [Abstract] [Full Text] [PDF]

				A. J. M. Thomson, M.R. Gazvani, S. J. Wood, S. C. Meacock, D.I. Lewis-Jones, and C. R. Kingsland Comparison of ovarian response in right and left ovaries in IVF patients Hum. Reprod., August 1, 2001; 16(8): 1694 - 1697. [Abstract] [Full Text] [PDF]

				F.P. Hohmann, J.S.E. Laven, F.H. de Jong, M.J.C. Eijkemans, and B.C.J.M. Fauser Low-dose exogenous FSH initiated during the early, mid or late follicular phase can induce multiple dominant follicle development Hum. Reprod., May 1, 2001; 16(5): 846 - 854. [Abstract] [Full Text] [PDF]

				N. Lahlou, N. Chabbert-Buffet, S. Christin-Maitre, E. Le Nestour, M. Roger, and P. Bouchard Main inhibitor of follicle stimulating hormone in the luteal–follicular transition: inhibin A, oestradiol, or inhibin B? Hum. Reprod., May 1, 1999; 14(5): 1190 - 1193. [Abstract] [Full Text] [PDF]

				F. J. Hayes, J. E. Hall, P. A. Boepple, and W. F. Crowley Jr. Differential Control of Gonadotropin Secretion in the Human: Endocrine Role of Inhibin J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1835 - 1841. [Full Text]

				C. K. Welt, K. A. Martin, A. E. Taylor, G. M. Lambert-Messerlian, W. F. Crowley Jr., J. A. Smith, D. A. Schoenfeld, and J. E. Hall Frequency Modulation of Follicle-Stimulating Hormone (FSH) during the Luteal-Follicular Transition: Evidence for FSH Control of Inhibin B in Normal Women J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2645 - 2652. [Abstract] [Full Text] [PDF]

				B. C. J. M. Fauser and A. M. van Heusden Manipulation of Human Ovarian Function: Physiological Concepts and Clinical Consequences Endocr. Rev., February 1, 1997; 18(1): 71 - 106. [Abstract] [Full Text]